

REGENERON PHARMACEUTICALS INC

Form 8-K

September 08, 2006

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 8-K  
CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934**

**Date of Report (Date of earliest event reported): September 8, 2006 (September 7, 2006)**

**REGENERON PHARMACEUTICALS, INC.**

**(Exact name of registrant as specified in its charter)**

**New York**

**000-19034**

**133444607**

(State or other jurisdiction of  
incorporation)

(Commission File Number)

**(I.R.S. Employer  
Identification Number)**

**777 Old Saw Mill River Road, Tarrytown, New  
York**

**10591-6707**

**(Address of principal executive offices)**

**(Zip Code)**

**(914) 347-7000**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01 Other Events**

On September 7, 2006, the Company issued a press release announcing that it was awarded a five-year grant from the National Institutes of Health (NIH) as part of the NIH's Knockout Mouse Project. The press release is included as Exhibit 99(a) to this Current Report on Form 8-K.

**Item 9.01 Financial Statements and Exhibits**

(c) Exhibits

99(a) Press Release of Regeneron Pharmaceuticals, Inc. dated September 7, 2006.

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

REGENERON PHARMACEUTICALS,  
INC.

Dated: September 8, 2006

By: /s/ Stuart Kolinski  
Stuart Kolinski  
Vice President and General Counsel

2

---

**Exhibit Index**

<b>Number</b>	<b>Description</b>
99(a)	Press Release of Regeneron Pharmaceuticals, Inc. dated September 7, 2006.

3